Form 4: Lynx1 Capital Management LP Increases Stake in TScan Therapeutics
SEC Form 4
Lynx1 Capital Management LP reports acquiring additional shares of TScan Therapeutics, increasing its beneficial ownership.
Summary
- Lynx1 Capital Management LP, along with Weston Nichols, filed a Form 4 detailing changes in beneficial ownership of TScan Therapeutics, Inc. (TCRX) common stock.
- On May 19, 2025, Lynx1 Capital Management LP acquired 1,388,794 shares at $1.2 per share, bringing their total indirect ownership to 6,746,141 shares.
- On May 20, 2025, they acquired an additional 1,200,000 shares at $1.2 per share, increasing their total indirect ownership to 7,946,141 shares.
- The shares are held by Lynx1 Master Fund LP and a managed account, with Lynx1 Capital Management LP serving as the investment manager.
- Weston Nichols, as the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, disclaims beneficial ownership except to the extent of his pecuniary interest.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing indicating increased ownership, which could be interpreted as a positive signal, but doesn't provide enough information to strongly influence sentiment.
Positives
- Lynx1 Capital Management LP increasing its stake in TScan Therapeutics could be seen as a positive signal, indicating confidence in the company's future prospects.
Risks
- The document itself doesn't explicitly mention risks, but the investment decisions of Lynx1 Capital Management LP are subject to market risks and the performance of TScan Therapeutics.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and significant shareholders, providing transparency to the market.
Stakeholder Impact
- Shareholders may view the increased stake by Lynx1 Capital Management LP as a positive sign.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Lynx1 Capital Management LP acquired 1,388,794 shares of TScan Therapeutics at $1.2 per share. |
| 05/20/2025 | Lynx1 Capital Management LP acquired 1,200,000 shares of TScan Therapeutics at $1.2 per share. |
| 05/21/2025 | Date of signature for the Form 4 filing by Lynx1 Capital Management LP and Weston Nichols. |
Keywords
TScan Therapeutics, Lynx1 Capital Management, beneficial ownership, Form 4, share acquisition, investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.